tirzepatide and long covid Can a GIP/GLP-1 dual receptor agonist help treat COVID? A new nationwide clinical trial led by scientists at the Scripps Research Translational Institute is putting that question to the test. The Scientists launch new trial for

Many people with Alzheimers develop insulin problems in their brains, similar to diabetes

In a new trial, a pharmaceutical company is now testing the first GLP-1 agonist made specifically for cats For pet owners and vets struggling to control their moggy's weight, this could be a major breakthrough

A rare but serious adverse effect is lactic acidosis, which occurs predominantly in patients with renal impairment, severe dehydration, or acute illness

Cross-linking changes compound these problems

*Findings published in a journal article by the National Library of Medicine in September 2022

A grassroots organization called #STOPTHEBOP seeks to protect access to these irreplaceable treatments